|
| Study ID | Sample size (T/C) | Design | Baseline characteristics | Intervention group | Control group | Duration | Primary outcome measures | Secondary outcome measures |
|
| Bao et al. 2013 [16] | 47 (23/24) | Dual-centre double-blind RCT | Age range: 44–82
Median duration of therapy: 426 days
Disease stage: N/A | CV4, CV6, CV12, bilateral LI4, MH6, GB34, ST36, KI3, BL65 | Sham acupuncture (nonpenetrating retractable needles) | 20 min, 8 weeks, weekly | (1) HAQ-DI
(2) pain VAS scores | N/A |
| Crew et al. 2010 [15] | 38 (20/18) | Single-centre double-blind RCT | Age range: 37–77
Median duration of therapy: 7/12 months
Disease stage: I, II, III | Standard TCM point prescription (not given) | Sham acupuncture (superficial needle insertion at non-acupoints) | 30 min, 6 weeks, biweekly | (1) BPI
(2) WOMAC
(3) M-SACRAH | FACT-G |
| Greenlee et al. 2016 [18] | 48 (25/23) | Single-centre double-blind RCT | Age range: 27–79
Median duration of therapy: 12 cycles
Disease stage: I, II, III | GB34, ST37, LI4, LI10, L3, L5, C5, C7 | Sham acupuncture (park sham collapsible needles at nonacupoints) | 30 min, 12 weeks, weekly | (1) BPI-SF
(2) FACT-NTX
(3) NPS-4 | FACT-TAX |
| He 2017 [13] | 64 (32/32) | Single-centre RCT | Age range: 18–75
Disease stage: I, II, IIIA | CV12, bilateral LV13, CV6, ST25, PC6, ST36 | Sham acupuncture (superficial needle insertion at nonacupoints) | 30 min, 1 week, thrice per week | (1) nausea level (0–3) | HADS |
| Hershman et al. 2018 [21] | 155 (101/54) | Multi-centre double-blind RCT | Age range: 34.1–80.6
Median duration of therapy: 1 year
Disease stage: I, II, III | Standards for reporting of controlled trials in acupuncture | Sham acupuncture (superficial needle insertion at nonacupoints) | 30–45 min, 1–6 weeks biweekly,
7–12 weeks weekly | (1) BPI-WP
(2) BPI-SF
(3) WOMAC
(4) M-SACRAH | (1) FACT-ES
(2) PROMIS PI-SF |
| Li 2017 [20] | 40 (20/20) | Single-centre RCT | Mean age (SD): 46.1 (9.369)
KPS: >80
Disease stage: I, II, III, IV | CV6, CV4, bilateral ST36, SP6, ST25, LV3, PC6 | No control treatment | 30 min, once | (1) Nausea level (0–3)
(2) Vomiting level (0–3) | N/A |
| Liu 2014 [17] | 140 (70/70) | Single-centre RCT | Mean age (SD): 51.16 (10.25)
Mean KPS (SD): 95.26 (1.38) | CV12, CV10, CV6, CV4, bilateral ST25, SP15, ST24 | No control treatment | 30 min, 3 days, twice everyday | (1) Nausea level (0–3)
(2) Vomiting level (0–3)
(3) Appetite level (0–3)
(4) Constipation score (0–5)
(5) Diarrhea score (0–5) | N/A |
| Lu et al. 2020 [26] | 33 (16/17) | Single-centre waitlist RCT | Age range: 26–71
Median duration of therapy: 17.3/13.3
Disease stage: I, II, III | Yin Tang, LI11, TW5, Baxie, SP9, ST36, SP6, K3, LR3, Qiduan | Waitlist control | 30 min, 8 weeks, 18 treatment | (1) PNQ
(2) FACT-NTX
(3) BPI-SF | EORTC QLQ-C30 |
| Mao et al. 2014 [12] | 41 (21/20) | Single-centre RCT | Joint pain for at least 3mo
Disease stage: I, II, III
BPI-WP: ≥4 | 4 local acupoints around the pain joint (not provided) | Sham acupuncture (nonpenetrating needles at nonacupoints) | 30 min, biweekly for 2 weeks, weekly for next 6 weeks | (1) BPI | HADS |
| Quinlan-Woodward et al. 2016 [19] | 30 (15/15) | Single-centre blind RCT | Mean age (SD): 58.1 (11.5)
All Caucasians | Standard TCM point prescription (not given) | No control treatment | 36 min, once | (1) Nausea level (0–10) | N/A |
| Shen et al. 2000 [14] | 70 (37/33) | Single-centre double-blind RCT | Mean age (SD): 44.7 (8.0)
KPS: >80 | PC6, ST36 | Sham acupuncture (superficial needle insertion near LU7, GB34) | 20 min,
5 days, once every day | (1) Emesis episodes | N/A |
| Shi 2019 [24] | 169 (85/84) | Single-centre RCT | Age range: 18–75
KPS: >60 | GV20, GV4, GV3, GV2, CV12, CV4, CV6, CV3, | Sham acupuncture (superficial needle insertion 20 mm next to real acupoints) | 30 min, 7 days, once every day | (1) Nausea level (0–4)
(2) Vomiting level (0–4) | (1) SAS
(2) SDS
(3) KPS |
| Tong et al. 2018 [22] | 75 (39/36) | Single-centre blind RCT | Age range: 21–55 (premenopausal)
Disease stage: I, II | DU20, EX-HN1, KI3, DU24, KI4, GB39, ST36 | No control treatment | 30 min, 5 days per week, 4 weeks for 2 courses | (1) FACT-COG
(2) AVLT | FACT-COG |
| Zhang 2018 [23] | 93 (48/45) | Single-centre RCT | Age range: 25–55
MoCA: <26
MMSE: 21–26 | DU20, EM1, D24, PC6, HT7, GB20, CV17, CV12, CV6 | Sham acupuncture (superficial needle insertion at nonacupoints) | 30 min, 8 weeks, biweekly | (1) MoCA
(2) MMSE | N/A |
| Zhang 2019 [25] | 104 (53/51) | Single-centre RCT | Age range: 30–55
Disease stage: I, II, III, IV
Patients with cognitive impairment | SP10, CV17, CV12, CV6, DU20, DU16, bilateral ST36, BI15, BI45, HT5, KD6 | Sham acupuncture (superficial needle insertion at nonacupoints) | 20 min, 8 weeks, biweekly | (1) MoCA
(2) MMSE | EORTC QLQ-C30 |
| Zhang et al. 2020 [27] | 83 (40/43) | Single-centre double-blind RCT | Mean age (SD): 47.9 (10.6)
Disease stage: I, II, IIIA
Under chemo (%): 73.3/78.7 | HT7, LI4, TE5, ST36, ST40, CV12, CV4, GV26, bilateral SP6 | Minimum acupuncture stimulation, bilateral BL7, LI10, BL59 | 30 min, 8 weeks, biweekly | (1) MoCA
(2) Forward digit span test
(3) Reverse digit span test | N/A |
|
